Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Apr 09
2024
Allogene Therapeutics Announces Q2 Investor Conference Participation
Learn More >
Mar 14
2024
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Learn More >
Mar 12
2024
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Learn More >
Mar 05
2024
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Learn More >
Feb 28
2024
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Learn More >
Feb 16
2024
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Learn More >
Jan 16
2024
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Learn More >
Jan 04
2024
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >
Jan 04
2024
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >
Jan 03
2024
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
Learn More >
View All